QSAR in Development of Antidepressants

More documents

Recommendations

Info

Conclusion • lead compound activity should be as efficient as current SSRIs yet faster response • QSAR done on 5-HT need to address NE
References • Phil Skolnick, P. P., Aaron Janowsky, Bernard Beer, Arnold S. Lippa Antidepressant-like actions of DOV 21,947: a "triple" reuptake inhibitor. European journal of pharmacology. 2003, 461, 99-104. • Kamal, A., et. al Chemoenzymatic synthesis of duloxetine and its enantiomer liase-catalyzed resolution of 3hydroxy-3-(2-thienyl) propanenitrile. Tetrahedron letters 2003, 44, 4783-4787 • Frazer, A. Antidepressants. Journal of Clinical Psychiatry 1997, 58, 9-25. • Schafer, W. R. Do Antidepressants Work? Prospects for Genetic Analysis of Drug Mechanisms. Cell 1999, 98, 551-554. • Evrard, D., Ping Zhou, Soo i, Dahui Zhou, Deborah L. Smith, Kelly M. Sullivan, Geoffrey A. Hornby, lee E. Schechter, Terrance H. Andree, and Richard E. Mewshaw Studies towards the next generation of antidepressants. Part 4: Derivatives of 4-(5fluoro-1H-indol-3- yl)cyclohexylamine with affinity for the serotonin transporter and the 5-HT1A receptor. Bioorganic & Medicinal Chemistry Letters 2005, 15, 911-914. • Owens, M. Selectivity of Antidepressants from Monoamine Hypothesis of Depression to the SSRI Revolution and Beyond. Journal of Clinical Psychiatry 2004, 65, 5-10.
Page 1 and 2: The Next Generation of Antidepressa
Page 3 and 4: Depression as a Disease • 1 out 5
Page 5 and 6: Serotonin Hypothesis • serotonerg
Page 7 and 8: Serotonin effect Phil Skolnick, P.
Page 9 and 10: Project Aim • explore a faster ac
Page 11 and 12: QSAR Design • Create training set
Page 13 and 14: Why use GFA • builds multiple mod
Page 15 and 16: • r 2 =.87 QSAR results • valid
Page 17 and 18: Strategy Nh 2 fluoxetine F Cl O H N
Page 19 and 20: Synthetic scheme S antidepressants
Page 21: Synthetic scheme

QSAR in Development of Antidepressants

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?